中和剂选择试验中和产物组稀释液对结果的影响

试验表明，在中和剂选择试验中，中和产物组活菌计数用磷酸盐缓冲液作稀释液，可能掩盖中和产物的抑菌作用。改用中和产物溶液作稀释液，可避免上述结果。     

Sysmex XT-1800型血细胞分析仪国产配套稀释液的研究

目的：探讨自研血细胞分析仪配套稀释液,研制适用于Sysmex XT-1800血细胞分析仪的稀释液,以替代昂贵的原装试剂.方法：对原装试剂进行理化分析,根据分析结果配制两者PH值,电导率,离子浓度等指标相近的稀释液,并做一系列对比试验.结果：自配和进口稀释液理化指标一致,检测85份抗凝静脉样本,所得11项主要指标均数相近,经配对资料t检验,p值均〉0.05,相关系数均〉0.90,而且自配试剂重复性、稳定性良好.结论：自配Sysmex XT-1800稀释液完全可以替代原装稀释液.     

Effect of Hydrophilic Diluents on the Release Profile of Griseofulvin from Tablet Formulations

Studies have shown that when compressing drugs with low aqueous solubility, the solubility of diluents selected is very crucial as it influences the disintegration, dissolution and bioavailability of such drugs. Based on these reports, the present study was undertaken to investigate the effect of some commonly used hydrophilic tablet diluents (lactose, sucrose, mannitol and dextrose) on the in vitro release properties of griseofulvin from compressed tablets. Griseofulvin granules and tablets were prepared using the wet granulation method. Tablet properties evaluated as a function of the diluents used include, hardness, friability, dissolution profile and dissolution efficiency at 60 min. Results obtained indicated variability in griseofulvin release in the presence of the diluents. The relative enhanced dissolution effects of the four hydrophilic diluents is in the order of dextrose>sucrose>lactose>mannitol. All the griseofulvin tablet batches produced exhibited a better drug release (in terms of rate and extent of release) than a commercially available tablet sample of griseofulvin (Fulcin^®). The results of the dissolution efficiency (DE_60min) are 91.7, 83.5, 48.7, 35.3 and 15.6% for dextrose, sucrose, lactose, mannitol and fulcin^®, respectively. The overall results indicated that dextrose or sucrose can be utilised to improve the in vitro release profile and hence in vivo bioavailability of griseofulvin from compressed tablets.     

稀释剂含量对光固化纳米羟基磷灰石复合材料机械性能的影响

目的比较不同含量稀释剂对新型光固化纳米羟基磷灰石复合材料机械性能的影响。方法按照双酚A-甲基丙烯酸缩水甘油酯（B is-GMA）与双甲基丙烯酸二缩三乙二醇酯（TEGDMA）的质量比8∶2、7∶3、6∶4合成三份树脂基质,然后与经过KH-570表面处理后的纳米羟基磷灰石按质量比为45∶55共混,制备成3组光固化纳米羟基磷灰石复合树脂,分别记为A组、B组、C组,A2型卡瑞斯玛复合树脂为对照组记为D组,每组制作5个试件,测定各组固化深度、抗压强度和挠曲强度,用方差分析比较其差异。结果随着稀释剂比例的增加,实验组的固化深度变化不明显,与对照组有明显统计学差异（P〈0.05）;实验组压缩强度与挠曲强度均呈现先升高后下降的趋势,其中B组的抗压强度和挠曲强度均与对照组无统计学差异（P〉0.05）。结论树脂基质B is-GMA与稀释剂TEGDMA的质量比为7∶3时,新型光固化纳米羟基磷灰石复合材料机械性能较佳,固化深度能够达到国际标准。     

铝热反应熔附成型陶瓷涂覆技术的研究

采用铝热反应熔附成型技术在普通碳素钢管内壁涂覆一层较为均匀致密的陶瓷层。分析了烯释剂添加量和粉体充填密度对反应蔓延速度以陶瓷涂层厚度的影响。     

三烷基氧膦萃取草酸的稀释剂效应和盐析效应

测定了11种稀释剂对三烷基氧膦萃取草酸的分配比D的影响。结果表明，若按D的大小来排列，则芳烃类>烷烃类>卤代烃类。考察了无机盐MgCl2、NaCl、KCl对萃取过程的影响，发现D随着盐浓度的增加先下降后上升，探讨了产生这一现象的原因。     

Crystallization,Melting and Morphology of Syndiotactic/Atactic Polystyrene Blends: Molecular Weight Effects of Atactic Polystyrene

Summary: Molecular weight (MW) effects of atactic polystyrene (aPS) on the morphologies and crystallization kinetics of syndiotactic polystyrene (sPS) blends have been investigated, and miscibility was confirmed for all the sPS/aPS blends. Addition of aPS(M) or aPS(L) leads to a significant increase in the entropy of mixing and gives rise to a pronounced decrease in the equilibrium melting temperature of the blends. On heating from the glassy state, the crystallization peak temperature of the sPS/aPS(H) blend increased with increasing aPS content due to a dilution effect, whereas those of sPS/aPS(M) and sPS/aPS(L) decreased mainly due to enhanced chain mobility. On cooling from the melt state, the crystallization peak temperature decreased with increasing aPS content regardless of the aPS MW. A higher activation energy is required for the sPS component transport from the miscible melt to the growth front in the sPS/aPS(L), suggesting that extra energy is required for the demixing process. Interspherulitic segregation of aPS diluents was evident in the sPS/aPS(L) blends, while interfibrillar segregation morphology was obtained in the sPS/aPS(H) as well as the sPS/aPS(U) blends.

SEM images of sPS/aPS blends 50/50(L) at 230 °C (C) and 70/30(L) at 250 °C (D).     

前列腺素E1脂微球载体制剂对体外循环中患者血液系统的影响

目的探讨前列腺素E1脂微球载体制剂(Lipo-PGE₁)对体外循环(CPB)中患者血液系统的影响。方法将20例施行心脏瓣膜置换术患者随机分为观察组和对照组各10例,观察组于CPB开始至结束匀速3ng／(kg·min)泵入Lipo-PGE1,预充液中加入5ng／mL,对照组用等容量生理盐水。测定肝素化后(T₁)、CPB开始30min(T₂)及CPB结束即刻(T₃)、CPB结束1h(T₄)、CPB结束24h(T₅)5个时点血浆血栓素B₂(TXB₂)、6-酮-前列腺素F1α(6-Keto-PGF1α)、游离血红蛋白(F-HB)的浓度值。结果两组中TXB2、6-Keto-PGF1α及其比值、F-HB在CPB过程中均显著升高,CPB结束时达峰值,各时点与T1比较差异有统计学意义(P<0.05)。在相应时间点,观察组6-Keto-PGF1α明显高于对照组,TXB₂、TXB₂／6 Keto-PGF1α、F-HB明显低于对照组(P<0.05)。结论Lipo-PGE₁能纠正CPB中TXB₂与6-Keto-PGF1α比值的失衡,改善患者的凝血功能;降低血浆中F-HB的浓度,减轻由红细胞破坏引起的机体溶血,对患者的血液系统有一定的保护作用。     

丙型肝炎病毒抗体酶联免疫诊断试剂中酶结合物稀释液对酶结合物稳定性影响的研究

目的通过对不同酶结合物稀释液的丙型肝炎病毒(HCV)抗体酶联免疫诊断试剂的稳定性对比试验,优选出最佳的酶结合物稀释液用于HCV抗体诊断试剂的生产。方法用不同酶结合物稀释液的HCV抗体酶联免疫诊断试剂,对丙型肝炎质控血清进行检测,检测出4℃试剂盒实验结果各样品S/CO值和37℃3d试剂盒实验结果各样品S/CO值,将实验结果进行对比。结果以中性PBST(加有Tween-20的磷酸盐缓冲液)为缓冲液,以BSA(牛血清白蛋白)和Casein(酪蛋白)无关蛋白作稳定剂的酶结合物稀释液的试剂的实验结果明显优于其余试剂。结论以PBST为缓冲液,以BSA和Casein无关蛋白作稳定剂组成酶结合物稀释液适用于HCV抗体酶联免疫诊断试剂的生产。     

泌乳宝冲剂催乳作用的实验研究

目的研究泌乳宝冲剂的催乳作用。 [方法 ]通过对母鼠每天腹腔注射NaF 15× 10 - 6 注射体积 10mL/kg ,连续 7d观察小鼠动物缺乳模型及受试药物和正常产褥期乳汁分泌量的影响 ,用放免方法检测血清泌乳素水平并观察组织学改变。 [结果 ]泌乳宝冲剂 6× 10 - 3、12× 10 - 3灌胃 (ig)给药对NaF致小鼠缺乳模型均有显著增加乳量的作用 (P <0 .0 1) ,可明显增加缺乳动物血清泌乳素的含量 (P <0 .0 5 ) ,使乳腺组织呈高度泌乳状态。对正常小鼠母鼠乳汁量及仔鼠体重也有明显增加作用。 [结论 ]泌乳宝冲剂对缺乳状态下的小鼠乳汁分泌有明显作用。